Kastrationsresistentes Prostatakarzinom 2015

Translated title of the contribution: Castration resistant prostate cancer 2015

A. S. Merseburger*, A. Böker, M. A. Kuczyk, C. A. Von Klot

*Corresponding author for this work


Prostate cancer is still the most common urological cancer of the elderly man. In some patients, a metastatic prostate cancer arises which may remain a stable disease for years with palliative antiandrogen therapy. On average, after 3-4 years, affected men develop a PSA rise and disease progression with the formation of a so-called castration-resistant disease. 5 years ago cytotoxic chemotherapy with docetaxel was the only life-prolonging treatment option in this situation. In the last 5 years, the results of randomised phase III studies have led to the approval of 5 new agents for the treatment of metastatic castration resistant prostate cancer (mCRPC). The results and approval status of the substances, Abiraterone, Enzalutamide, Cabazitaxel, Sipuleucel-T and radium-223 are described below. In addition, some aspects of sequential therapy and possible future molecular approaches are discussed.

Translated title of the contributionCastration resistant prostate cancer 2015
Original languageGerman
JournalAktuelle Urologie
Issue number1
Pages (from-to)59-65
Number of pages7
Publication statusPublished - 01.01.2015


Dive into the research topics of 'Castration resistant prostate cancer 2015'. Together they form a unique fingerprint.

Cite this